COMMUNIQUÉS West-GlobeNewswire

Transactions of Managers and Closely Associated Persons
06/01/2026
Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of shares in [...]
Transactions of Managers and Closely Associated Persons
06/01/2026
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 7,007,321 shares [...]
Beacon Behavioral Partners Enters 2026 Poised for Continued Growth Following Regional Expansion and Senior Leadership Additions
06/01/2026
Pivotal Investments in People, Technology and Infrastructure Position the Organization for Accelerated Impact BATON ROUGE, La., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners (BBP) , one of the nation’s [...]
SOUND Behavioral Health Chosen for Washington’s CCBHC Pre-Certification Cohort
06/01/2026
As part of the state’s pre-certification cohort, SOUND is leading the shift toward integrated, equitable, and outcomes-driven behavioral health services. SEATTLE, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SOUND Behavioral [...]
LifeLabs Named Canada’s Most Trusted Health Diagnostic Brand for Fourth Year in a Row
06/01/2026
This recognition highlights LifeLabs commitment to empowering healthier Canadians Toronto, Ontario, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeLabs, Canada’s leading provider of laboratory diagnostics, has been voted by [...]
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
06/01/2026
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of [...]
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
06/01/2026
Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluation Compelling anti-inflammatory activity of G1090N was evidenced through [...]
GENFIT : Profil de sécurité favorable en Phase 1 et forte activité anti-inflammatoire pour G1090N, actif clé dans l’ACLF
06/01/2026
Les résultats de Phase 1 confirment que le candidat-médicament expérimental G1090N présente un profil de sécurité et de tolérabilité favorable, justifiant la poursuite de son évaluation clinique Une activité anti- [...]
Clinical Neurology Specialists Partnering with Leading International Nonprofit to Accelerate Alzheimer’s Research in Las Vegas
06/01/2026
Collaboration to Improve Access to Study for Alzheimer’s Disease LAS VEGAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Today, Global Alzheimer’s Platform Foundation ® (GAP) and Clinical Neurology Specialists (CNS) announced [...]
Ipsen – Half year statement – 2025 12 31
06/01/2026
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF PARIS, 06 JANUARY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that under the liquidity agreement entrusted by IPSEN S.A. to NATIXIS [...]
Ipsen - Bilan semestriel - 31 12 2025
06/01/2026
Bilan semestriel du contrat de liquidité entre IPSEN et NATIXIS ODDO BHF PARIS, FRANCE, 06 JANVIER 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui qu’au titre du contrat de liquidité confié par IPSEN S.A [...]
Transparency Notification from Shareholders
06/01/2026
Ghent, Belgium, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Transparency Notification from Shareholders PRESS RELEASE REGULATED INFORMATION 6 January 2026, 6:00 pm CET Ghent, Belgium – 6 January 2026 – Sequana Medical NV ( [...]
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
06/01/2026
Newly added funding closes critical gap and enables planned trial initiation in early 2026 GILBERT, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- A Race Against Blindness, the Arizona-based 501(c)(3) nonprofit founded by Dr [...]
Teclison, Inc. to Participate in ASCO Gastrointestinal Cancers Symposium
06/01/2026
PRINCETON, N. J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive [...]
PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID Program
06/01/2026
TUSCALOOSA, Ala., Jan. 06, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics , a clinical-stage biopharmaceutical company developing antiviral therapies for infection-associated chronic illnesses including Long COVID, today [...]
Dewpoint Therapeutics Launches Initiative to Build Viral Condensate Phenomics Atlas for HPV
06/01/2026
Dewpoint to create a large-scale condensate phenomics atlas to illuminate cellular drivers of HPV-associated diseases Funded by the Gates Foundation to advance global health by improving understanding of HPV infection [...]
SoldierStrong Announces Annual SoldierScholar Recipients For 2025
06/01/2026
STAMFORD, Conn, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Delivering on its commitment to assist military veterans in taking a significant academic step forward in life after service, the national nonprofit SoldierStrong today [...]
Medtech Incubator Partners with Leap Distributors to Support U.S. Market Expansion Efforts
06/01/2026
SCOTTSDALE, Arizona and DALLAS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Medtech Incubator announced today that it has partnered with Leap Distributors to support market adoption and expansion activities for emerging medical [...]
QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session
06/01/2026
Unaudited update reflects revenue growth, positive operating income, removal of convertible debt, and improved cash flow profile entering 2026. Company reports $1.99 million in revenue for the nine months ended [...]

Pages